Vaxcyte, Inc.·4

Mar 17, 4:55 PM ET

Wright-Mitchell Jane 4

4 · Vaxcyte, Inc. · Filed Mar 17, 2021

Insider Transaction Report

Form 4
Period: 2021-03-15
Mitchell Jane Wright
General Counsel
Transactions
  • Exercise/Conversion

    Common Stock

    2021-03-15$2.03/sh+2,500$5,0754,062 total
  • Sale

    Common Stock

    2021-03-15$27.01/sh1,013$27,3613,049 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2021-03-152,500199,968 total
    Exercise: $2.03Exp: 2029-03-20Common Stock (2,500 underlying)
  • Sale

    Common Stock

    2021-03-15$27.49/sh1,487$40,8781,562 total
Footnotes (4)
  • [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  • [F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $26.28 to $27.27. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $27.355 to $27.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F4]1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION